Tag
#FBIO
-
2026
-
Journey Medical Corporation to Participate in A.G.P.’s Annual Virtual Healthcare Conference
-
Fortress Biotech to Participate in A.G.P.’s Annual Virtual Healthcare Conference
-
FBIO – 10-Q
-
FBIO – 8-K
-
Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
-
Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
-
Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026
-
Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference
-
FBIO – DEF 14A
-
FBIO – DEFA14A
-
FBIO – CORRESP [Cover]
-
Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™
-
FBIO – 10-K
-
FBIO – 8-K
-
Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights
-
FBIO – 8-K
-
Fortress Biotech’s Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million
-
Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights
-
Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights
-
FBIO – SCHEDULE 13D/A [Amend]
-
Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026
-
Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026
-
UPDATE: Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
-
UPDATE: Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
-
Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million